Rigel Pharmaceuticals RIGL Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's proceeds from exercises of stock options and other stock issuances?
- Rigel Pharmaceuticals (RIGL) reported proceeds from exercises of stock options and other stock issuances of $321K in Q1 2026.
- How has Rigel Pharmaceuticals's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Rigel Pharmaceuticals's proceeds from exercises of stock options and other stock issuances decreased by 33.7% year-over-year, from $484K to $321K.
- What is the long-term trend for Rigel Pharmaceuticals's proceeds from exercises of stock options and other stock issuances?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's proceeds from exercises of stock options and other stock issuances has grown at a 14.1% compound annual growth rate (CAGR), from $4.78M to $8.1M.